NEKTAR THERAPEUTICS — Director's Dealing 2021

Dec 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2021-12-16

Reporting Person: Zalevsky Jonathan (Chief R&D Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-16	Common Stock	A	52950	$0.00	Acquired	285034	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-16	Stock Option	$13.22	A	94000	Acquired	2029-12-15	Common Stock (94000)	Direct

Footnotes

F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service.

F2: This stock option vests over four years from the date of grant in equal monthly installments based on continued service.